| abstract |
REFERRING TO A PYRAZOLO [1,5-a] PYRIMIDINE DERIVATIVE HETEROCYCLIC COMPOUND OF FORMULA (A), WHERE R1 IS A 5 TO 7 MEMBER HETEROCYCLIC RING OPTIONALLY SUBSTITUTED WITH NO, CHO, CN, N3, AMONG OTHERS; R2 IS A BICYCLE RING OF 9 TO 14 MEMBERS, A HETEROARYL RING OF 5 TO 7 MEMBERS, A HETEROARYL RING OF 9 TO 14 MEMBERS, AMONG OTHERS; R3, R4 AND R5 ARE CN, C1-C6 ALKYL, C (O) OR7, AMONG OTHERS; R7 IS H, C1-C6 ALKYL, HETEROARYL RING FROM 5 TO 10 MEMBERS, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: 3- (7- {6 - [(1-AZABICYCLO [2.2.2] OCT-4-ILMETYL) AMINO] PYRIDIN-3-IL} -2-PYRIDIN-4-ILPIRAZOLO [1,5-a ] PYRIMIDIN-3-IL) PHENOL, 3- (7- {6 - [(3S) -1-AZABICYCLO [2.2.2] OCT-3-ILAMINO] PYRIDIN-3-IL} -2-PYRIDIN-4-ILPIRAZOLO [1,5-a] PYRIMIDIN-3-IL) PHENOL, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS INHIBIT THE TYROSINE KINASES, K-Raf AND Raf KINASES AND ARE USEFUL IN THE TREATMENT OF CANCER CELLS |